Cancer Family
Thymus Neoplasm
CI-CAN-00000366Explore in graph →
Non-malignant104 active trials1 approved drugs1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000366Explore in graph →
Clinical trials
283 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05940272 | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | recruiting | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02393157 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL(O-ICE) | recruiting | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06186726 | Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311955 | Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311968 | The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor | recruiting | Phase 2 | 55 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05667948 | Molecular Analysis and Treatment Options of Thymic Malignancies | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05377307 | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | recruiting | — | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06781450 | Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context(PRIMICI) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06796517 | Immunotherapy in Lymphoma | recruiting | — | 72 | Sung-Soo ParkOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06730308 | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06692062 | Hypofractionated Radiotherapy for Thymic Epithelial Tumors | recruiting | N/A | 100 | Rongrong ZhouOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05683886 | A Study of KC1036 in Patients with Advanced Thymic Tumors | recruiting | Phase 2 | 30 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | recruiting | Phase 2 | 120 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06421805 | Establishing Prospective Mediastinal Tumor Database of PUMCH(MTDPUMCH) | recruiting | — | 2,000 | Peking Union Medical College HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06339255 | Italian Observational Study on CAR-T Therapy for Lymphoma(CART-SIE) | recruiting | — | 5,300 | Paolo CorradiniOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06301945 | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors(INTHYM) | recruiting | — | 1,020 | Erasmus Medical CenterOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06029621 | Robot-assisted vs VATS for Thymoma | recruiting | N/A | 304 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)(Artemis) | recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04822077 | Study on Proton Radiotherapy of Thymic Malignancies(PROTHYM) | recruiting | N/A | 40 | Ass. Prof. Jan NymanNETWORK | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04522687 | Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer | recruiting | — | 500 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 21, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 9, 2025source: clinicaltrials